Plain-English translation of NCT07469098 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our PTSD research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , combined with psychotherapy, can help people recover from PTSD (post-traumatic stress disorder) after the October 7, 2023 events. The study compares two approaches: receiving the medication and therapy in small groups or in individual one-on-one sessions. MDMA is not a treatment by itself, but rather a medication that enhances the effectiveness of therapy by increasing trust and reducing fear responses.
Current PTSD treatments—including medications and therapy—only help a small portion of people who suffer from this condition. This trial exists to test whether this medication combined with psychotherapy can lead to stronger, longer-lasting recovery for trauma survivors.
You likely qualify if…
You likely don't qualify if…
Participants will attend preparatory sessions before receiving the medication, then return for dosing sessions where they receive MDMA in a divided dose while medical staff monitor vital signs. Depending on which group they're randomly assigned to, they'll either receive therapy in a small group of up to seven people with similar trauma experiences, or in individual one-on-one sessions. After each dosing session, participants stay overnight at the study site and are driven home the next day. They'll also attend follow-up integration sessions and complete questionnaires throughout the study to track their progress.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Israel